Deliver Your News to the World

C2i Genomics Announces Successful Evaluation of Whole Genome-Based Residual Disease Test Across Multiple Solid Cancer models

C2i Genomics will collaborate with AstraZeneca to explore the C2i Minimal Residual Disease (MRD) test for clinical research & drug development.

New York, New York – WEBWIRE

"This collaboration has generated promising results by providing ultra-sensitive and accurate cancer detection and monitoring across multiple solid cancers,” said Asaf Zviran, CEO and co-founder of C2i Genomics.

C2i Genomics, a cancer intelligence company, today announced an extension of a collaboration with AstraZeneca (LSE/STO/Nasdaq: AZN), a global science-led biopharmaceutical company.

The two companies have collaborated to evaluate the potential of whole-genome minimal residual disease (MRD) testing across solid cancers, with the goal of enhancing oncology treatment and supporting clinical trial recruitment and monitoring. C2i genomics has completed AstraZeneca’s BeyondBio Innovation Hub’s program for Israeli start-ups. Using artificially generated samples to reproduce varying levels of circulating tumor DNA (ctDNA) expected to be found in tumors, this collaboration provided early evidence that the C2i assay can sensitively detect ctDNA (down to 0.002% allelic frequency). Building on this work, AstraZeneca will further evaluate and validate the C2i Genomics platform across a panel of patient-derived samples using their in-house sequencing capabilities and expertise.

The industry is continuing to transform the way cancer is detected with the recent developments of cheaper, more cost-effective accessible whole genome sequencing (WGS) technologies. With the convergence of reduced prices of whole-genome sequencing, the increase of capacity and throughput of global cloud infrastructure, and the combined technological developments in machine learning and signal processing, C2i Genomics is at the forefront of an inflection point that will profoundly change cancer treatment monitoring and clinical decisions.

The non-invasive detection of circulating tumor DNA (ctDNA) from plasma has been shown to have clinical value for the detection of Minimal Residual Disease (MRD), the emergence of resistance, and the prediction of treatment response. New MRD technologies aim to provide greater cancer detection sensitivity by expanding methods beyond small, personalized panels.

C2i Genomics’ MRD technology applies whole-genome sequencing and artificial intelligence to a small blood sample to provide ultra-sensitive cancer detection. This technology aims to eliminate the need to develop a patient-specific assay, enabling high-performance, personalized monitoring and rapid turnaround across multiple solid cancers with reduced operational complexity.

“This collaboration has generated promising results by providing ultra-sensitive and accurate cancer detection and monitoring across multiple solid cancers,” said Asaf Zviran, CEO and co-founder of C2i Genomics. “We’re looking forward to our continued collaboration with AstraZeneca to see where the power of our technologies can support the development of more effective cancer treatments for the patients that urgently need it.”

C2i has expanded its SaaS solution across the globe, utilizing a cloud-based platform to perform cancer tumor burden monitoring. The collaboration with AstraZeneca comes after a period of successful partnerships and momentum, most recently with Karkinos Healthcare in India, OncoDNA across the EU, into China with NuProbe Global and an expansion in the greater US with Premier Inc.

For companies interested in deploying C2i Genomics, please visit

About C2i Genomics:

Founded in 2019, C2i Genomics has created the world’s leading cancer treatment intelligence platform that uses low-input blood (only 3-4mL blood) and offers ultra-sensitive whole-genome sequencing cancer detection and monitoring. With headquarters in NYC, CLIA lab in Cambridge MA, and an R&D center in Israel, C2i’s SaaS solution utilizes a cloud-based platform to perform cancer tumor burden monitoring on a global scale, leveraging the thousands of already installed genome sequencers around the world. Using cutting-edge scientific breakthroughs, growing genomic and clinical databases, and sophisticated computation and AI, C2i enables high precision personalized medicine, reduced cancer treatment costs, and accelerated drug development. The company has raised over $112 million from leading institutional investors including Casdin Capital, NFX, Silver Lake, Duquesne Family Office, Section 32 and iGlobe Partners. For more information, please visit C2i was named to the 2021 CB Insights Digital 150 list and awarded the 2022 North American Digital Cancer Monitoring Platform Technology Innovation Leadership Award by Frost & Sullivan.

( Press Release Image: )


 Liquid Biopsy
 Cancer Testing
 Precision Medicine

This news content may be integrated into any legitimate news gathering and publishing effort. Linking is permitted.

News Release Distribution and Press Release Distribution Services Provided by WebWire.